BioVaxys Technology Corp.: BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021

VANCOUVER, BC, Nov. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that interim results from its ongoing

Related Keywords

United States ,Ohio ,Canada ,United Kingdom ,Ohio State University ,Vancouver ,British Columbia ,Frankfurt ,Brandenburg ,Germany ,British ,Canadian ,David Berd ,Davin Shinedling ,Kenneth Kovan ,Biovaxys Technology Corp ,Jba Inc ,Biovaxys Or Company ,Company Covid ,Prnewswire Biovaxys Technology Corp ,Vaxys Technology ,Ohio State ,Chief Medical Officer ,Vaxys President ,Chief Operating Officer Kenneth Kovan ,Biovaxys Technology ,British Columbia Registered ,Frankfurt Bourse ,Abiovaxys ,Technology ,Orp ,Sarbecovirus ,Vaccine ,Interim ,Data ,Excellent ,Merging ,Safety ,Tolerability ,Profile ,021 ,